Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Blood (2015) 126 (23): 3848.

https://doi.org/10.1182/blood.V126.23.3848.3848

Published: 2015

Journal Articles

HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival

Marc Poch Martell, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Fotios V. Michelis, MDPhD, Jieun Uhm, MD, Feras Alfraih, MD, Mohamed Shanavas, MD FRACP, FRCPA, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis Kim, MDPhD

Blood (2014) 124 (21): 3915.

https://doi.org/10.1182/blood.V124.21.3915.3915

Published: 2014

Journal Articles

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, Tony Panzerella, Anthea Lau, Naheed Alam, MBBS,MD, Aaron D Schimmer, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Andre C Schuh, MD FRCPC, Mohamed Shanavas, MD FRACP, FRCPA, Karen W.L. Yee, MDFRCPC, Vikas Gupta, MD FRCP, FRCPath

Blood (2014) 124 (21): 3180.

https://doi.org/10.1182/blood.V124.21.3180.3180

Published: 2014

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Mohamed Shanavas, MD, FRACP, FRCPA, Hans A. Messner, MD, PhD, Suzanne Kamel-Reid, PhD, Eshetu G Atenafu, MSc, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura Ellis, NP, MN, RN (EC), Jeffrey H. Lipton, MD, PhD

Blood (2013) 122 (21): 5501.

https://doi.org/10.1182/blood.V122.21.5501.5501

Published: 2013

Journal Articles

Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cellis a Risk Factor, But Not HLA-Mismatch With No Adverse Impact On Transplant Outcomes

Jieun Uhm, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 3293.

https://doi.org/10.1182/blood.V122.21.3293.3293

Published: 2013

Journal Articles

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, Dennis Kim, MD

Blood (2013) 122 (21): 3303.

https://doi.org/10.1182/blood.V122.21.3303.3303

Published: 2013

Journal Articles

Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable

Mohamed Shanavas, MD, FRACP, FRCPA, Nada Hamad, MBBS Hons, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 4601.

https://doi.org/10.1182/blood.V122.21.4601.4601

Published: 2013

NARROW

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cellis a Risk Factor, But Not HLA-Mismatch With No Adverse Impact On Transplant Outcomes

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only